SCHEMBL4168013

SCHEMBL4168013

COc1cccc(C(=O)C(=O)Nc2ccc3c(=O)onc(C)c3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.48
NPC1 O15118 6/20 0.48
RAB9A P51151 6/20 0.48
POLB P06746 3/20 0.48
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 1/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
NR3C1 P04150 3/20 0.44
PGR P06401 2/20 0.44
NR3C2 P08235 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178107 0.88 NR3C1 (0.45) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL4163146 0.86 NR3C1 (0.53) NR3C1PGRNR3C2AR
SCHEMBL4167811 0.83 NR3C1 (0.48) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL4167696 0.82 NR3C1 (0.49) RAB9ACES2MEN1KMT2ANR3C1
SCHEMBL4173274 0.80 NR3C1 (0.50) NPC1RAB9ANR3C1PGRNR3C2
SCHEMBL4167078 0.79 NR3C1 (0.47) NPC1RAB9ANR3C1PGRNR3C2
SCHEMBL4168021 0.78 NR3C1 (0.41) NPC1RAB9ANR3C1PGRNR3C2
SCHEMBL4172484 0.78 GFER (0.46) NPC1RAB9ANR3C1PGRNR3C2
SCHEMBL13909324 0.78 NR3C1 (0.43) NPC1RAB9ANR3C1PGRNR3C2
SCHEMBL4173498 0.77 NR3C1 (0.49) NPC1RAB9ASMN1; SMN2KDM4ENR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075989-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AG (DE) 2009-03-19 US disclosed
US-20090075989-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AG (DE) 2009-03-19 US disclosed
US-20090075989-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AG (DE) 2009-03-19 US disclosed
WO-2008077646-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075989-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS NR5A1, CYP19A1, GPER1 HPGD 106/4885NPC1 3356/4885RAB9A 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.